Faecalibacterium prausnitziiinhibits interleukin-17 to ameliorate colorectal colitis in rats

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zhang, Mingming ^a,b   Qiu, Xinyun ^a   Zhang, Hao ^c   Yang, Xiaotong ^a   Hong, Na ^a   Yang, Yonghua ^c   Chen, Hui ^d   Yu, Chenggong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NANJING UNIVERSITY   (China)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BONE MARROW DERIVED DENDRITIC CELL; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; FAECALIBACTERIUM PRAUSNITZII; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTE DIFFERENTIATION; MALE; METABOLITE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PROTECTION; RAT; SPLEEN CELL; SUPERNATANT; TH17 CELL; TISSUE LEVEL; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CELL DIFFERENTIATION; CLOSTRIDIALES; COLON; CYTOLOGY; DISEASE MODEL; METABOLISM; PATHOLOGY; PHYSIOLOGY; RECTUM; SPRAGUE DAWLEY RAT;

FAECALIBACTERIUM; RATTUS;

ADULT; ANIMALS; BODY WEIGHT; CELL DIFFERENTIATION; CLOSTRIDIALES; COLITIS; COLON; DISEASE MODELS, ANIMAL; FATTY ACIDS; HUMANS; IN VITRO TECHNIQUES; INTERLEUKIN-17; RATS; RATS, SPRAGUE-DAWLEY; RECTUM; TH17 CELLS;

EID: 84907484487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109146     Document Type: Article

References (34)

1. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard D.C., et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234.
2. Hundorfean G, Neurath MF, Mudter J (2012) Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 18: 180-186.
3. Holtta V, Klemetti P, Sipponen T., Kociubinski G, Westerholm-Ormio M, et al. (2008) IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflammatory Bowel Diseases 14: 1175-1184.
4. Hoeve MA, Savage ND, de Boer T, Langenberg DM, de Waal Malefyt R, et al. (2006) Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. European Journal of Immunology 36: 661-670.
5. Mathur AN, Chang HC, Zisoulis D.G., Kapur R., Belladonna ML, et al. (2006) T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype. Blood 108: 1595-1601.
6. Zhang Z, Zheng M, Bindas J., Schwarzenberger P, Kolls JK (2006) Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflammatory Bowel Diseases 12: 382-388.
7. Yen D, Cheung J, Scheerens H., Poulet F, McClanahan T, et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. Journal of Clinical Investigation 116: 1310-1316.
8. Fuss IJ, Becker C, Yang Z., Groden C, Hornung RL, et al. (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12: 9-15
9. Wallace TC, Guarner F, Madsen K, Cabana MD, Gibson G, et al. (2011) Human gut microbiota and its relationship to health and disease. Nutr Rev 69: 392-403.
10. Suau A, Rochet V, Sghir A., Gramet G, Brewaeys S, et al. (2001) Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Systematic and Applied Microbiology 24: 139-145.
11. Cato EP, Salmon CW, Holdeman LV (1974) Eubacterium-Cylindroides (Rocchi) Holdeman and Moore - Emended Description and Designation of Neotype Strain. International Journal of Systematic Bacteriology 24: 256-259.
12. Yin L, Laevsky G, Giardina C (2001) Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 276: 44641-44646.
13. Hamer HM, Jonkers D, Venema K., Vanhoutvin S, Troost FJ, et al. (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27: 104-119.
14. Sokol H, Pigneur B, Watterlot L., Lakhdari O, Bermudez-Humaran LG, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America 105: 16731-16736.
15. Machiels K, Joossens M, Sabino J., De Preter V, Arijs I, et al. (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63: 1275-1283.
16. Cao Y, Shen J, Ran ZH (2014) Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterology Research and Practice.
17. Miquel S, Martin R, Rossi O., Bermudez-Humaran LG, Chatel JM, et al. (2013) Faecalibacterium prausnitzii and human intestinal health. Current Opinion in Microbiology 16: 255-261.
18. Sarrabayrouse G, Bossard C, Chauvin J.M., Jarry A., Meurette G, et al. (2014) CD4CD8aa Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease. Plos Biology 12.
19. Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G (2007) Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 149: 470-479.
20. Martin R, Chain F, Miquel S., Lu J, Gratadoux JJ, et al. (2014) The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models. Inflammatory Bowel Diseases 20: 417-430.
21. Tanabe S, Kinuta Y, Saito Y (2008) Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation. International Journal of Molecular Medicine 22: 181-185.
22. Foligne B, Nutten S, Steidler L., Dennin V, Goudercourt D, et al. (2006) Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: Technical and microbiological aspects. Digestive Diseases and Sciences 51: 390-400.
23. Neurath MF, Fuss I, Kelsall B.L., Stuber E., Strober W (1995) Antibodies to Interleukin-12 Abrogate Established Experimental Colitis in Mice. Journal of Experimental Medicine 182: 1281-1290.
24. Foligne B, Nutten S, Grangette C., Dennin V, Goudercourt D, et al. (2007) Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology 13: 236-243.
25. Lopez P, Gueimonde M, Margolles A., Suarez A (2010) Distinct Bifidobacterium strains drive different immune responses in vitro. International Journal of Food Microbiology 138: 157-165.
26. Inaba K, Inaba M, Romani N., Aya H, Deguchi M, et al. (1992) Generation of Large Numbers of Dendritic Cells from Mouse Bone-Marrow Cultures Supplemented with Granulocyte Macrophage Colony-Stimulating Factor. Journal of Experimental Medicine 176: 1693-1702.
27. Brown RS, Wahl RL (1993) Overexpression of Glut-1 Glucose-Transporter in Human Breast-Cancer - an Immunohistochemical Study. Cancer 72: 2979-2985.
28. Jing H, Vassiliou E, Ganea D (2003) Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol 74: 868-879.
29. Loos M, Remaut E, Rottiers P., De Creus A (2009) Genetically Engineered Lactococcus lactis Secreting Murine IL-10 Modulates the Functions of Bone Marrow-Derived Dendritic Cells in the Presence of LPS. Scandinavian Journal of Immunology 69: 130-139.
30. Qiu X, Zhang M, Yang X., Hong N, Yu C (2013) Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis 7: e558-568.
31. Fujino S, Andoh A, Bamba S., Ogawa A, Hata K, et al. (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70.
32. Nielsen OH, Kirman I, Rudiger N., Hendel J, Vainer B (2003) Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gas-troenterol 38: 180-185.
33. Breuer RI, Soergel KH, Lashner B.A., Christ ML, Hanauer SB, et al. (1997) Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomised, placebo controlled trial. Gut 40: 485-491.
34. Di Sabatino A, Morera R, Ciccocioppo R., Cazzola P, Gotti S, et al. (2005) Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 22: 789-794.